Roche halts lung drug combo test

Share this article:

Roche has canned its exploratory combination of onartuzumab and Tarceva among previously treated, advanced non-small cell lung cancer patients with MET-positive tumors.

The company said in a statement Monday that it halted Phase-III studies “due to a lack of clinically meaningful efficacy.”

The company also said the findings have prompted a review of its other onartuzumab clinical trials.

Monday's news follows a Reuters story that indicates that although Roche and Novartis have been buddying up of late that a merger is not in the works.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.